Canabo Medical (TSXV:CMM, OTCQB:CAMDF) entered a collaborative agreement with Terra Life Sciences to work on cannabinoid-based treatments.

As quoted in the press release:

The intended outcome of the agreement will be to develop new cannabinoid-based formulations to target specific medical conditions and illnesses such as chronic pain or anxiety. In addition, the agreement specifies both parties will conduct joint medical research and testing, and share future revenues from any new medical formulations and IP developed.

Key aspects of the Agreement include both companies working jointly to identify, develop and conduct medical research on new cannabinoid formulations designed to assist patients with specific conditions such as pain management and anxiety. The Agreement also provides for revenue sharing on any licensing revenues resulting from any newly developed products.

Click here to read the full press release.

Source: New feed